MENIS, JESSICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.074
AS - Asia 883
EU - Europa 451
SA - Sud America 184
AF - Africa 164
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 11
Totale 4.781
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.008
SG - Singapore 279
CN - Cina 200
HK - Hong Kong 146
BR - Brasile 137
IT - Italia 59
SE - Svezia 56
VN - Vietnam 49
RU - Federazione Russa 44
PL - Polonia 43
DE - Germania 39
FI - Finlandia 30
KR - Corea 29
NL - Olanda 29
IN - India 16
GB - Regno Unito 15
FR - Francia 14
IQ - Iraq 13
LY - Libia 12
TR - Turchia 12
AT - Austria 10
CA - Canada 10
AM - Armenia 9
ES - Italia 9
UG - Uganda 9
AD - Andorra 8
AR - Argentina 8
CI - Costa d'Avorio 8
JP - Giappone 8
KZ - Kazakistan 8
MX - Messico 8
PS - Palestinian Territory 8
XK - ???statistics.table.value.countryCode.XK??? 8
AE - Emirati Arabi Uniti 7
EC - Ecuador 7
IR - Iran 7
ML - Mali 7
NA - Namibia 7
SA - Arabia Saudita 7
TL - Timor Orientale 7
DJ - Gibuti 6
GF - Guiana Francese 6
HR - Croazia 6
ID - Indonesia 6
NC - Nuova Caledonia 6
PH - Filippine 6
PY - Paraguay 6
RS - Serbia 6
UZ - Uzbekistan 6
AO - Angola 5
BE - Belgio 5
CH - Svizzera 5
CM - Camerun 5
CU - Cuba 5
CY - Cipro 5
EG - Egitto 5
IE - Irlanda 5
KG - Kirghizistan 5
LT - Lituania 5
MD - Moldavia 5
ME - Montenegro 5
NI - Nicaragua 5
NP - Nepal 5
PA - Panama 5
SI - Slovenia 5
SK - Slovacchia (Repubblica Slovacca) 5
TN - Tunisia 5
TT - Trinidad e Tobago 5
UA - Ucraina 5
YT - Mayotte 5
ZA - Sudafrica 5
BJ - Benin 4
CG - Congo 4
CO - Colombia 4
DK - Danimarca 4
EE - Estonia 4
ET - Etiopia 4
GP - Guadalupe 4
IS - Islanda 4
JO - Giordania 4
MG - Madagascar 4
MR - Mauritania 4
PE - Perù 4
PK - Pakistan 4
RE - Reunion 4
SO - Somalia 4
TZ - Tanzania 4
UY - Uruguay 4
VE - Venezuela 4
AF - Afghanistan, Repubblica islamica di 3
AL - Albania 3
AU - Australia 3
AZ - Azerbaigian 3
BD - Bangladesh 3
BF - Burkina Faso 3
CD - Congo 3
CL - Cile 3
CR - Costa Rica 3
CV - Capo Verde 3
CW - ???statistics.table.value.countryCode.CW??? 3
Totale 4.659
Salva come PNG Salva come JPEG
Città #
Fairfield 625
Ashburn 306
Woodbridge 238
Chandler 234
Cambridge 217
Seattle 216
Houston 206
Singapore 154
Wilmington 151
Hong Kong 143
Ann Arbor 84
Santa Clara 64
San Diego 63
Beijing 61
Boardman 48
Medford 42
Princeton 42
Bytom 38
Des Moines 38
Dearborn 35
Padova 29
Hefei 27
Seoul 27
Helsinki 23
New York 22
Ogden 18
Dong Ket 16
Roxbury 14
Jinan 13
São Paulo 12
Ho Chi Minh City 11
Nanjing 11
Hanoi 9
Kampala 9
Munich 9
Andorra la Vella 8
Chicago 8
Los Angeles 8
Nanchang 8
Rio de Janeiro 8
Shenyang 8
Yerevan 8
Abidjan 7
Bamako 7
Dili 7
Djibouti 6
Kazan' 6
London 6
Noumea 6
Nuremberg 6
Pristina 6
Tashkent 6
Bishkek 5
Cayenne 5
Duncan 5
Havana 5
Istanbul 5
Panama City 5
Tokyo 5
Turku 5
Addis Ababa 4
Amman 4
Baghdad 4
Columbus 4
Cotonou 4
Falkenstein 4
Frankfurt am Main 4
Guayaquil 4
Luanda 4
Madrid 4
Managua 4
Porto Alegre 4
Quezon City 4
Redwood City 4
San Francisco 4
Stockholm 4
Taizhou 4
Vienna 4
Windhoek 4
Antananarivo 3
Baku 3
Banjul 3
Belgrade 3
Belo Horizonte 3
Benghazi 3
Brazzaville 3
Buffalo 3
Campinas 3
Castries 3
Chisinau 3
Dakar 3
Dar es Salaam 3
Dublin 3
Dushanbe 3
Harare 3
Jiaxing 3
Les Abymes 3
Lusaka 3
Mamoudzou 3
Medina 3
Totale 3.553
Salva come PNG Salva come JPEG
Nome #
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study) 201
A computational index derived from whole-genome copy number analysis is a novel tool for prognosis in early stage lung squamous cell carcinoma 178
Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer 160
18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy 143
INTEGRATED CARE PATHWAYS in LUNG CANCER: A QUALITY IMPROVEMENT PROJECT 142
Eribulin (Halaven): A new, effective treatment for women with heavily pretreated metastatic breast cancer 140
Brain metastases from gastrointestinal tumours: Tailoring the approach to maximize the outcome 138
The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613 137
Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer 136
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 135
Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer 133
HER-2 expression in brain metastases from colorectal cancer and corresponding primary tumors: A case cohort series 127
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 125
Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era 124
Checkpoint Inhibitors in SCLC: How Much Can We Trust in Randomized Cohorts of Phase I/II Trials? 119
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 118
Prospects of targeted and immune therapies in SCLC 117
Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN) 114
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection 114
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 114
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA) 113
Combination of Immunotherapy and Radiotherapy—The Next Magic Step in the Management of Lung Cancer? 113
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study 111
Fulminating septic shock from Clostridium perfringens in an early breast cancer patient with severe myalgia after docetaxel treatment 110
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 110
Long-term update of the 24954 EORTC phase III trial on larynx preservation 106
Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: A subset analysis of EORTC 24971 study 104
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation 102
The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics 99
Treatment duration of checkpoint inhibitors for NSCLC 99
Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064) 98
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 97
Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines? 96
Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer 96
TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: A randomized phase II EORTC trial 94
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score) 93
New clinical research strategies in thoracic oncology: Clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response 91
Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061) 91
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients. Results from a multicenter Italian observational study 88
Responding to the challenges of international collaborations between the east and the west – Report of the first JCOG–EORTC symposium and a perspective from young JCOG and EORTC investigators 82
Methodology of clinical trials in lung cancer 64
MET inhibition in lung cancer 57
Totale 4.829
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.666
article - articoli 16.666
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.332
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021501 0 0 37 19 17 61 73 41 85 35 81 52
2021/2022706 38 73 96 56 63 42 57 56 21 19 53 132
2022/2023386 71 65 3 57 51 37 0 25 57 5 13 2
2023/2024234 9 30 24 21 12 39 20 11 25 2 20 21
2024/2025890 1 15 20 21 145 39 25 78 111 31 159 245
2025/2026874 186 347 341 0 0 0 0 0 0 0 0 0
Totale 4.829